Abstract: 【Abstract】 Objective〓To investigate whether the expression of TOPOⅡ and P53 expression in breast cancer could predict the efficacy of neoadjuvant chemotherapy. Methods〓This research retrospectively analyzed 185 patients, who were diagnosed as invasive ductal carcinomas in stage Ⅱ-Ⅲ, admitted in the Breast Cancer Center in our hospital and accepted NAC from October 2011 to August 2015. Immunohistochemical assay was used to detect the TOPOⅡ and P53 protein levels of 185 breast cancer tissues obtained by core needle biopsy before neoadjuvant chemotherapy. The relationship of TOPOⅡ and P53 expression with clinicopathological characteristics as well as prognosis of neoadjuvant chemotherapy was statistically analyzed. Results〓The objective response rate (ORR) of patients with positive TOPOⅡ expression was significantly higher than that of patients with negative TOPOⅡ expression. The clinical complete response (cCR ) proportion of patients with positive P53 expression was larger than that of patients with negative P53 expression. The patients with both positive TOPOⅡ and P53 expression not only achieved a higher rate of ORR but had a larger proportion of cCR than the case in patients not with both positive TOPOⅡ and P53 expression. Conclusion〓The protein levels of TOPOⅡ and P53 showed predictive value of the efficacy of neoadjuvant chemotherapy based on anthracyclines.

Key words: Breast cancer, TOPOⅡ, P53, Neoadjuvant chemotherapy

摘要： 【摘要】〓目的〓本研究旨在检测化疗前乳腺癌组织中TOPOⅡ和P53的表达情况,探讨二者与新辅助化疗疗效之间的关系。方法〓本研究回顾性分析了我院乳腺肿瘤医学部自2011年10月至2015年8月接受以蒽环类为基础新辅助化疗的Ⅱ~Ⅲ期浸润性导管癌患者185例,化疗前用空心针穿刺活检,按常规免疫组化的方法检测TOPOⅡ、P53的表达情况。统计学分析TOPOⅡ、P53的表达水平与患者临床病理特征及与新辅助化疗效果的关系。结果〓TOPOⅡ阳性的患者中达到客观缓解的较表达阴性比例更大(P=0.002),P53阳性的患者中达到临床完全缓解的比例比阴性患者更大(P=0.015),TOPOII及P53均为阳性的患者达到临床完全缓解及客观缓解的比例均较高(P=0.010及P=0.027)。结论〓新辅助化疗前乳腺癌组织中TOPOⅡ和P53的表达水平对新辅助化疗有良好的预测效果。

关键词: 乳腺癌, 拓扑异构酶Ⅱ, P53, 新辅助化疗